[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse SLC27A6

Summary
SymbolSLC27A6
Namesolute carrier family 27 (fatty acid transporter), member 6
Aliases FATP6; VLCS-H1; FACVL2; ACSVL2; fatty-acid-Coenzyme A ligase, very long-chain 2; FATP-6; VLCSH1; fatty acid ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein Cell membrane, sarcolemma Note=In heart is exclusively located on the sarcolemma in areas juxtaposed with small blood vessels where it colocalizes CD36.
Domain PF00501 AMP-binding enzyme
PF13193 AMP-binding enzyme C-terminal domain
Function

Involved in translocation of long-chain fatty acids (LFCA) across the plasma membrane. Thought to function as the predominant fatty acid protein transporter in heart.

> Gene Ontology
 
Biological Process GO:0000038 very long-chain fatty acid metabolic process
GO:0001676 long-chain fatty acid metabolic process
GO:0006631 fatty acid metabolic process
GO:0006820 anion transport
GO:0006869 lipid transport
GO:0010876 lipid localization
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015908 fatty acid transport
GO:0015909 long-chain fatty acid transport
GO:0046942 carboxylic acid transport
Molecular Function GO:0004467 long-chain fatty acid-CoA ligase activity
GO:0005319 lipid transporter activity
GO:0015245 fatty acid transporter activity
GO:0015645 fatty acid ligase activity
GO:0016874 ligase activity
GO:0016877 ligase activity, forming carbon-sulfur bonds
GO:0031957 very long-chain fatty acid-CoA ligase activity
Cellular Component GO:0042383 sarcolemma
> KEGG and Reactome Pathway
 
KEGG hsa03320 PPAR signaling pathway
Reactome R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-804914: Transport of fatty acids
R-HSA-425397: Transport of vitamins, nucleosides, and related molecules
Summary
SymbolSLC27A6
Namesolute carrier family 27 (fatty acid transporter), member 6
Aliases FATP6; VLCS-H1; FACVL2; ACSVL2; fatty-acid-Coenzyme A ligase, very long-chain 2; FATP-6; VLCSH1; fatty acid ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC27A6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSLC27A6
Namesolute carrier family 27 (fatty acid transporter), member 6
Aliases FATP6; VLCS-H1; FACVL2; ACSVL2; fatty-acid-Coenzyme A ligase, very long-chain 2; FATP-6; VLCSH1; fatty acid ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC27A6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC27A6
Namesolute carrier family 27 (fatty acid transporter), member 6
Aliases FATP6; VLCS-H1; FACVL2; ACSVL2; fatty-acid-Coenzyme A ligase, very long-chain 2; FATP-6; VLCSH1; fatty acid ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC27A6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1480.535
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3910.503
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0230.955
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.0840.0844
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3530.735
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472.010.091
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5830.418
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6250.651
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6710.679
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0360.94
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0360.959
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.8630.0201
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC27A6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.14.170.339
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.15.160.373
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.85.917.90.197
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.19.1140.596
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.87.48.40.452
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.215.42.81
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC27A6
Namesolute carrier family 27 (fatty acid transporter), member 6
Aliases FATP6; VLCS-H1; FACVL2; ACSVL2; fatty-acid-Coenzyme A ligase, very long-chain 2; FATP-6; VLCSH1; fatty acid ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC27A6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC27A6
Namesolute carrier family 27 (fatty acid transporter), member 6
Aliases FATP6; VLCS-H1; FACVL2; ACSVL2; fatty-acid-Coenzyme A ligase, very long-chain 2; FATP-6; VLCSH1; fatty acid ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC27A6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC27A6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC27A6
Namesolute carrier family 27 (fatty acid transporter), member 6
Aliases FATP6; VLCS-H1; FACVL2; ACSVL2; fatty-acid-Coenzyme A ligase, very long-chain 2; FATP-6; VLCSH1; fatty acid ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC27A6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC27A6
Namesolute carrier family 27 (fatty acid transporter), member 6
Aliases FATP6; VLCS-H1; FACVL2; ACSVL2; fatty-acid-Coenzyme A ligase, very long-chain 2; FATP-6; VLCSH1; fatty acid ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC27A6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC27A6
Namesolute carrier family 27 (fatty acid transporter), member 6
Aliases FATP6; VLCS-H1; FACVL2; ACSVL2; fatty-acid-Coenzyme A ligase, very long-chain 2; FATP-6; VLCSH1; fatty acid ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC27A6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC27A6
Namesolute carrier family 27 (fatty acid transporter), member 6
Aliases FATP6; VLCS-H1; FACVL2; ACSVL2; fatty-acid-Coenzyme A ligase, very long-chain 2; FATP-6; VLCSH1; fatty acid ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC27A6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.